Summary
A controlled double blind clinical trial was performed comparing therapeutic efficacy of hidrosmin versus diosmin in patients suffering from chronic venous insufficiency with varicose symptomatology in the inferior limbs.

Ten patients were treated with hidrosmin and other 10 with diosmin randomly.

The controls carried out during the trial were as follows: basal control before the beginning of the trial and therapeutic controls on days 15, 30, 60 and 90 of the study. With that aim, clinical examinations and different explorations were performed: phisical exam, phlebography, electrocardiogram, ophthalmological examination and biochemical analyses (hemogram, globular sedimentation rate, platelet counts, etc.).

The clinical therapeutic efficacy of hidrosmin in the treatment of chronic venous insufficiency of inferior limbs was superior to the diosmin in most of the studied parameters even though a lower posology was employed.

By means of these effects, it reduces the caliber of dilated varicose veins and restores valvular functioning.

At the same time as it increases the resistance rate of microvases, hidrosmin controls the excess of permeability, responsible for the appearance of local edemas.

Finally, it has been proven that hidrosmin also has a favourable effect on microcirculation in the sense that it increases erythrocytic deformability and decreases blood viscosity, which helps even more to correct venous stasis, starting with the microcirculation unit.

Our objective in this this study was to compare the therapeutic efficacy and clinical tolerance of hidrosmin preparations versus diosmin, in patients suffering from chronic venous processes and venous insufficiency.

Material and method

A total of ten patients were treated with hidrosmin and another 10 with diosmin.

Both the clinical staff who followed the patient's evolution and the patient himself ignored which of the two preparations was being used for treatment.

The employed inclusion criteria were accepting patients of both sexes, aged 25 to 70, who had suffered from venous diseases which could be included in the following clinical patterns: chronic venous insufficiency, varicose syndrome, trophic skin disorders due to venous alterations, postphlebitic syndrome and alteration of oedemas due to difficulties in venous return.

The average age in both groups was 46 ± 9 years for the hidrosmin group and 47 ± 8 for the diosmin group. Their weight was 78 ± 9 kilos in the hidrosmin group and 74,5 ± 4 for the diosmine one. Sex distribution was proportional in both of them.

As a whole, there were no basal differences between the two groups which could justify a different clinical evolution, so both groups were considered homogeneous.

Patients with severe cardiac, renal or haepatic diseases, pregnant -or possibly pregnant- or lactating women, patients who from the beginning were not able to finish the study or patients with proved hypersensibility to similar medicines were not included in the study.

Introduction

The product F-117 or hidrosmin is a soluble derivative of 7-Ramnoglucoside of 5, 7, 3-trihydroxy, 4 metoxyflavone (diosmin), and is pharmacologically characterized by performing a selective activity on venomotricity.

Through experimentation, hidrosmin has been proven to perform two fundamental actions: restoration of an adequate venous tone, and the increase of resistance index in microvessels.

Medication
Each patient received two kinds of pharmaceutical formulae:

A. A liquid formula to be taken orally in drops
The evaluation of the objective parameters was also performed according to this scale.

Discussion of the results

The evolution of the studied parameters is explained in the following.

No changes were observed in the patients’ A.T., taken at the time of consultation and, except for a few oscillations which do not have any statistical value, the figures of A.T.s. at the end of the study were similar to those found at the start.

Basal figures of 141/88 were taken at the start in the hidrosmin group, whereas a basal mean of 148/90 was taken for the diosmin group.

The patients’ general state was defined as good in all the cases, and was kept likewise until the end of the trial, with no objective variations.

The patients’ pain in those limbs involved developed as follows according to the groups:

<table>
<thead>
<tr>
<th>Group</th>
<th>Control Basal</th>
<th>15</th>
<th>30</th>
<th>60</th>
<th>90</th>
</tr>
</thead>
<tbody>
<tr>
<td>H</td>
<td>1.4</td>
<td>0.8</td>
<td>0.4</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>D</td>
<td>1.2</td>
<td>0.4</td>
<td>0.4</td>
<td>0.6</td>
<td>0.6</td>
</tr>
</tbody>
</table>

That is, in the hidrosmin group the starting point is a light to medium pain, which develops until reaching a minimum one.

In the diosmin group the start is a less painful, only light, basal situation, and after a temporary recovery, pain increases on the days 60 and 90 of the treatment to reach a worse final situation than in the hidrosmin group.

The sensation of heaviness in the lower limbs developed according to the following chart:

<table>
<thead>
<tr>
<th>Group</th>
<th>Control Basal</th>
<th>15</th>
<th>30</th>
<th>60</th>
<th>90</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hidrosmin</td>
<td>1.8</td>
<td>1.0</td>
<td>0.6</td>
<td>0.6</td>
<td>0.2</td>
</tr>
<tr>
<td>Diosmin</td>
<td>1.4</td>
<td>1.2</td>
<td>1.2</td>
<td>1.2</td>
<td>1.2</td>
</tr>
</tbody>
</table>

Starting from a worse basal situation for the hidrosmin group, the achieved improvement is more important than in the diosmin group, where after an improvement during the two first weeks of treatment, the situation is stabilised and finally was worse than in the hidrosmin group (p<0.05, according to Fisher’s exact probability calculation).

As peripheral pulses are concerned, there was no important variation during the treatment, because except for one patient in the diosmin group whose peripheral pulse was weak and did not change during the treatment, the peripheral pulse was easily felt in the rest of the patients.

The sensation of local tension developed as follows:

<table>
<thead>
<tr>
<th>Group</th>
<th>Control Basal</th>
<th>15</th>
<th>30</th>
<th>60</th>
<th>90</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hidrosmin</td>
<td>1.4</td>
<td>1.0</td>
<td>0.6</td>
<td>0.4</td>
<td>0.4</td>
</tr>
<tr>
<td>Diosmin</td>
<td>1.2</td>
<td>1.0</td>
<td>0.4</td>
<td>0.4</td>
<td>0.4</td>
</tr>
</tbody>
</table>

Summarising, it is again something similar to what happens with the rest of the symptomatology, i.e., starting from a slightly worse situation in the hidrosmin group, the patients’ state is asymptomatic by the end of the treatment, whereas in the diosmin group, although a certain recovery is achieved, the final situation is not completely asymptomatic.

Paraesthesias develop as follows from the following chart:

<table>
<thead>
<tr>
<th>Group</th>
<th>Control Basal</th>
<th>15</th>
<th>30</th>
<th>60</th>
<th>90</th>
<th>60</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hidrosmin</td>
<td>1.8</td>
<td>1.0</td>
<td>0.6</td>
<td>0.6</td>
<td>0.2</td>
<td>1.2</td>
</tr>
<tr>
<td>Diosmin</td>
<td>1.4</td>
<td>1.2</td>
<td>1.2</td>
<td>1.2</td>
<td>1.2</td>
<td>1.2</td>
</tr>
</tbody>
</table>

That is, in the diosmin group the starting point is a light to medium pain, which develops until reaching a minimum one.

In the diosmin group the start is a less painful, only light, basal situation, and after a temporary recovery, pain increases on the days 60 and 90 of the treatment to reach a worse final situation than in the hidrosmin group.

The sensation of heaviness in the lower limbs developed according to the following chart:

<table>
<thead>
<tr>
<th>Group</th>
<th>Control Basal</th>
<th>15</th>
<th>30</th>
<th>60</th>
<th>90</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hidrosmin</td>
<td>1.8</td>
<td>1.0</td>
<td>0.6</td>
<td>0.6</td>
<td>0.2</td>
</tr>
<tr>
<td>Diosmin</td>
<td>1.4</td>
<td>1.2</td>
<td>1.2</td>
<td>1.2</td>
<td>1.2</td>
</tr>
</tbody>
</table>

Starting from a worse basal situation for the hidrosmin group, the achieved improvement is more important than in the diosmin group, where after an improvement during the two first weeks of treatment, the
As the state of the skin and its colour are concerned, there are no important changes during the treatment, although it must be observed that the first level of alteration was never passed in the basal visit or, in other words, alterations found in this respect at the beginning of the treatment were of little importance. Therefore, the fact that there was no noticeable recovery would be logical to a certain extent.

The evolution of oedema is satisfactory in both groups. However, while the perimeter reduction of the limb was achieved in 80% of the patients included in the hidrosmin group, in the diosmin group it only happened in half of the cases. The limb perimeter was normal in 20% of the cases in the hidrosmin group, while it only happened in one case in the diosmin group.

As for the existence of ulcers, there were two patients-one for each group- who showed this damage. The patient in the hidrosmin group recovered favourably but did not achieve complete recovery, passing from a level 2 ulcer to a level 1 ulcer at the end of the treatment. However, in the diosmin group patient, the first level ulcer did not modify, keeping the same level at the end of the treatment.

No important modifications which could justify haemodynamic changes in the lower limbs were observed in the patients' weight.

The performed phlebographic tests did not show relevant differences in any of the two treatments. There were no electrographic alterations, and the outlines obtained at the end of the study did not change with regard to the basal plot.

The performed analitical controls were within the normal limits, except for some statistically irrelevant modifications.

The patients' cooperation in their treatment was good and using drops as dosage did not represent a problem.

No adverse reactions appeared except in one diosmin group patient who had a sensation of nausea between the third and the sixth day of treatment, which did not oblige to its suspension. It disappeared spontaneously.

Nor were there any alterations in the performed ophthalmological examinations.

Conclusions

The efficacy of hidrosmin in treating venous insufficiency was superior in most of the studied parameters to that of diosmin, even though a lower posology was employed.

It should be observed that the subjective recovery in hidrosmin group patients (heaviness, pain, local tenderness, cramps, etc.) is much higher than it could be expected from the objective data (phlebography, trophism, skin colour, evolution of the oedema, etc.).

No significant adverse reactions appeared.

No analytical, electrocardiographic or ophthalmologic alterations appeared during the treatment.

The pharmacological formula was well accepted by most of the patients and the posology was followed well adjusted to the treatment. As a whole, patients did not show any kind of intolerance to the employed medication.

Bibliography


